SCHEMBL10089395

SCHEMBL10089395

CCc1cccc(-c2cccc(Oc3ccccc3)c2)c1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
BCL2 P10415 1/20 0.50
KDM4E B2RXH2 2/20 0.49
ALDH1A1 P00352 2/20 0.49
TDP1 Q9NUW8 1/20 0.49
TSHR P16473 2/20 0.46
FFAR1 O14842 2/20 0.46
FFAR4 Q5NUL3 2/20 0.46
HSD17B10 Q99714 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
PTGS2 P35354 1/20 0.45
HTT P42858 1/20 0.45
TP53 P04637 1/20 0.45
AGXT P21549 1/20 0.44
LTA4H P09960 2/20 0.44
MAOB P27338 1/20 0.44
CETP P11597 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5407250 0.89 KDM4E (0.58) KDM4EALDH1A1TDP1TSHRHSD17B10
SCHEMBL10089394 0.88 ALDH1A1 (0.51) BCL2KDM4EALDH1A1TDP1TSHR
SCHEMBL30358275 0.82 ALDH1A1 (0.50) KDM4EALDH1A1TDP1TSHRHSD17B10
SCHEMBL9488681 0.82 ALDH1A1 (0.50) KDM4EALDH1A1TDP1TSHRHSD17B10
SCHEMBL3037130 0.82 BCL2 (0.67) BCL2PTGS2TP53AGXT
SCHEMBL2879014 0.82 LTA4H (0.63) ALDH1A1TSHRFFAR1FFAR4SMN1; SMN2
SCHEMBL18015799 0.81 MAOB (0.56) BCL2AGXTMAOB
SCHEMBL18102828 0.81 MRGPRX4 (0.62) BCL2FFAR1FFAR4AGXTMAOB
SCHEMBL22435435 0.81 TSHR (0.52) KDM4EALDH1A1TDP1TSHRFFAR1
Water SCHEMBL9719807 0.81 BCL2 (0.65) BCL2PTGS2TP53AGXT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120010283-A1 MODULATION OF ANXIETY THROUGH BLOCKADE OF ANANDAMIDE HYDROLYSIS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-01-12 US disclosed
US-8003693-B2 Modulation of anxiety through blockade of anandamide hydrolysis THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-08-23 US disclosed
US-20090048337-A1 Modulation of anxiety through blockade of anandamide hydrolysis THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-02-19 US disclosed
US-7176201-B2 Modulation of anxiety through blockade of anandamide hydrolysis THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048337-A1 Modulation of anxiety through blockade of anandamide hydrolysis FAAH, FAAH2, CNR2 BCL2 2904/4885KDM4E 919/4885ALDH1A1 681/4885
US-20120010283-A1 MODULATION OF ANXIETY THROUGH BLOCKADE OF ANANDAMIDE HYDROLYSIS FAAH, FAAH2, CNR2 BCL2 2653/4885KDM4E 938/4885ALDH1A1 734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.